Beyond Air reaffirms CY2026 revenue guidance of $8 million
XAIR•Beyond Air reaffirmed calendar 2026 revenue guidance of $8 million, excluding its second-generation LungFit PH system, and reiterated its 2027 outlook of $16 million to $18 million, assuming FDA clearance enables sales. Preliminary revenue for the quarter ended Sept. 30, 2026, was $2.3 million, up about 30% sequentially.
1. Revenue outlook
Beyond Air reaffirmed calendar 2026 revenue guidance of $8 million, excluding any contribution from its second-generation LungFit PH system. The company reiterated its calendar 2027 revenue outlook of $16 million to $18 million, assuming FDA clearance enables sales of the second-generation system. Preliminary revenue for the quarter ended Sept. 30, 2026, was $2.3 million, up about 30% sequentially, driven by adoption of first-generation LungFit PH.
